Home › Multiple Myeloma › Kansas › Kansas City
Multiple Myeloma clinical trials in Kansas City, KS
4 studies for Multiple Myeloma are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- University of Kansas Cancer Center, Kansas City
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Kansas City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- University of Kansas Cancer Center, Kansas City
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Atlanta, GA42 studies
- Boston, MA42 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- St. Louis, MO24 studies
- Rochester, MN24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Kansas City
- Cardiovascular Disease14 studies
- Heart Failure13 studies
- Obesity13 studies
- Interstitial Lung Diseases13 studies
- Cystic Fibrosis13 studies
- Breast Cancer12 studies
- Bladder Cancer12 studies
- Acute Myeloid Leukemia12 studies
- Prostate Cancer12 studies
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer11 studies
- COPD9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.